Non-steroidal anti-inflammatory drugs as host-directed therapy for tuberculosis: A systematic review

Frontiers in Immunology

Volumn 8, Issue JUN, 2017, Pages

  Kroesen, Vera M ^a,b   Gröschel, Matthias I ^c   Martinson, Neil ^d   Zumla, Alimuddin ^e,f   Maeurer, Markus ^g   van der Werf, Tjip S ^c   Vilaplana, Cristina ^b,h  

^a UNIVERSITY OF OLDENBURG   (Germany)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^g KAROLINSKA INSTITUTE   (Sweden)

^h INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Host directed therapies; Infectious diseases; Non steroidal anti inflammatory drugs; Systematic review; Tuberculosis

Indexed keywords

ACETYLSALICYLIC ACID; CARPROFEN; CELECOXIB; CYCLOPHOSPHAMIDE; DICLOFENAC; ETHIONAMIDE; IBUPROFEN; INDOMETACIN; ISONIAZID; NONSTEROID ANTIINFLAMMATORY AGENT; PYRAZINAMIDE; STREPTOMYCIN; URIC ACID;

ANTIBACTERIAL ACTIVITY; ANTIBODY TITER; ANTIINFLAMMATORY ACTIVITY; BACTERIAL LOAD; GRANULOMA; HEMIPARESIS; HEMIPLEGIA; HISTOLOGY; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; SURVIVAL; SYSTEMATIC REVIEW; TUBERCULOSIS; TUBERCULOUS MENINGITIS;

EID: 85021697307     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2017.00772     Document Type: Review

References (49)

1. Pai M, Behr MA, Dowdy D, Dheda K, Divangahi M, Boehme CC, et al. Tuberculosis. Nat Rev Dis Primers (2016) 2:16076. doi:10.1038/nrdp.2016.76
2. WHO. Treatment of Tuberculosis: Guidelines. 4th ed. Geneva: World Health Organization (2010).
3. Zumla A, Maeurer M, Host-Directed Therapies Network Consortium. Host-directed therapies for tackling multi-drug resistant tuberculosis: learning from the Pasteur-Bechamp debates. Clin Infect Dis (2015) 61(9):1432-8. doi:10.1093/cid/civ631
4. Ivanyi J, Zumla A. Nonsteroidal antiinflammatory drugs for adjunctive tuberculosis treatment. J Infect Dis (2013) 208(2):185-8. doi:10.1093/infdis/jit153
5. Zumla A, Maeurer M, Host-Directed Therapies NetworkChakaya J, Hoelscher M, Ntoumi F, et al. Towards host-directed therapies for tuberculosis. Nat Rev Drug Discov (2015) 14(8):511-2. doi:10.1038/nrd4696
6. Hawn TR, Matheson AI, Maley SN, Vandal O. Host-directed therapeutics for tuberculosis: can we harness the host? Microbiol Mol Biol Rev (2013) 77(4):608-27. doi:10.1128/MMBR.00032-13
7. Kiran D, Podell BK, Chambers M, Basaraba RJ. Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review. Semin Immunopathol (2016) 38(2):167-83. doi:10.1007/s00281-015-0537-x
8. Marzo E, Vilaplana C, Tapia G, Diaz J, Garcia V, Cardona PJ. Damaging role of neutrophilic infiltration in a mouse model of progressive tuberculosis. Tuberculosis (Edinb) (2014) 94(1):55-64. doi:10.1016/j.tube.2013.09.004
9. Berger VW, Alperson SY. A general framework for the evaluation of clinical trial quality. Rev Recent Clin Trials (2009) 4(2):79-88. doi:10.2174/157488709788186021
10. Schoeman JF, Janse van Rensburg A, Laubscher JA, Springer P. The role of aspirin in childhood tuberculous meningitis. J Child Neurol (2011) 26(8):956-62. doi:10.1177/0883073811398132
11. Horsfall PA, Plummer J, Allan WG, Girling DJ, Nunn AJ, Fox W. Double blind controlled comparison of aspirin, allopurinol and placebo in the management of arthralgia during pyrazinamide administration. Tubercle (1979) 60(1):13-24. doi:10.1016/0041-3879(79)90051-5
12. Petty TL, Dalrymple GV. Inhibition of pyrazinamide hyperuricemia by small doses of acetylsalicylic acid. Ann Intern Med (1964) 60:898-900. doi:10.7326/0003-4819-60-5-898
13. Vilaplana C, Marzo E, Tapia G, Diaz J, Garcia V, Cardona PJ. Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis. J Infect Dis (2013) 208(2):199-202. doi:10.1093/infdis/jit152
14. Byrne ST, Denkin SM, Zhang Y. Aspirin antagonism in isoniazid treatment of tuberculosis in mice. Antimicrob Agents Chemother (2007) 51(2):794-5. doi:10.1128/AAC.01145-06
15. Byrne ST, Denkin SM, Zhang Y. Aspirin and ibuprofen enhance pyrazinamide treatment of murine tuberculosis. J Antimicrob Chemother (2007) 59(2):313-6. doi:10.1093/jac/dkl486
16. Shroff KE, Sainis KB, Sengupta SR, Kamat RS. Role of antigen-presenting cells in variation in immunogenicity of mycobacteria. Clin Exp Immunol (1990) 79(2):285-90. doi:10.1111/j.1365-2249.1990.tb05192.x
17. Hernandez-Pando R, Orozco H, Mancilla R. T-cell lung granulomas induced by sepharose-coupled Mycobacterium tuberculosis protein antigens: immunosuppressive phenomena reversed with cyclophosphamide and indomethacin. Immunology (1995) 86(4):506-11.
18. Dutta NK, Kumar KA, Mazumdar K, Dastidar SG. In vitro and in vivo antimycobacterial activity of antiinflammatory drug, diclofenac sodium. Indian J Exp Biol (2004) 42(9):922-7.
19. Dutta NK, Mazumdar K, Dastidar SG, Park JH. Activity of diclofenac used alone and in combination with streptomycin against Mycobacterium tuberculosis in mice. Int J Antimicrob Agents (2007) 30(4):336-40. doi:10.1016/j.ijantimicag.2007.04.016
20. Hankey GJ, Eikelboom JW. Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events. Lancet Neurol (2010) 9(3):273-84. doi:10.1016/S1474-4422(10)70038-7
21. Kramnik I, Beamer G. Mouse models of human TB pathology: roles in the analysis of necrosis and the development of host-directed therapies. Semin Immunopathol (2016) 38(2):221-37. doi:10.1007/s00281-015-0538-9
22. Kimmey JM, Huynh JP, Weiss LA, Park S, Kambal A, Debnath J, et al. Unique role for ATG5 in neutrophil-mediated immunopathology during M. tuberculosis infection. Nature (2015) 528(7583):565-9. doi:10.1038/nature16451
23. Jamwal SV, Mehrotra P, Singh A, Siddiqui Z, Basu A, Rao KV. Mycobacterial escape from macrophage phagosomes to the cytoplasm represents an alternate adaptation mechanism. Sci Rep (2016) 6:23089. doi:10.1038/srep23089
24. Eisen DP, McBryde ES, Walduck A. Low-dose aspirin and ibuprofen's sterilizing effects on Mycobacterium tuberculosis suggest safe new adjuvant therapies for tuberculosis. J Infect Dis (2013) 208(11):1925-7. doi:10.1093/infdis/jit476
25. Saha B, Das G, Vohra H, Ganguly NK, Mishra GC. Macrophage-T cell interaction in experimental mycobacterial infection. Selective regulation of co-stimulatory molecules on Mycobacterium-infected macrophages and its implication in the suppression of cell-mediated immune response. Eur J Immunol (1994) 24(11):2618-24. doi:10.1002/eji.1830241108
26. Schoeman J, Mansvelt E, Springer P, van Rensburg AJ, Carlini S, Fourie E. Coagulant and fibrinolytic status in tuberculous meningitis. Pediatr Infect Dis J (2007) 26(5):428-31. doi:10.1097/01.inf.0000261126.60283.cf
27. Lammie GA, Hewlett RH, Schoeman JF, Donald PR. Tuberculous cerebrovascular disease: a review. J Infect (2009) 59(3):156-66. doi:10.1016/j.jinf.2009.07.012
28. Schoeman JF, Van Zyl LE, Laubscher JA, Donald PR. Effect of corticosteroids on intracranial pressure, computed tomographic findings, and clinical outcome in young children with tuberculous meningitis. Pediatrics (1997) 99(2):226-31. doi:10.1542/peds.99.2.226
29. Meintjes G, Wilkinson RJ, Morroni C, Pepper DJ, Rebe K, Rangaka MX, et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS (2010) 24(15):2381-90. doi:10.1097/QAD.0b013e32833dfc68
30. Misra UK, Kalita J, Nair PP. Role of aspirin in tuberculous meningitis: a randomized open label placebo controlled trial. J Neurol Sci (2010) 293(1-2):12-7. doi:10.1016/j.jns.2010.03.025
31. Ikonomidis I, Andreotti F, Economou E, Stefanadis C, Toutouzas P, Nihoyannopoulos P. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation (1999) 100(8):793-8. doi:10.1161/01.CIR.100.8.793
32. Maitra A, Bates S, Shaik M, Evangelopoulos D, Abubakar I, McHugh TD, et al. Repurposing drugs for treatment of tuberculosis: a role for non-steroidal anti-inflammatory drugs. Br Med Bull (2016) 118(1):138-48. doi:10.1093/bmb/ldw019
33. Schaller A, Sun Z, Yang Y, Somoskovi A, Zhang Y. Salicylate reduces susceptibility of Mycobacterium tuberculosis to multiple antituberculosis drugs. Antimicrob Agents Chemother (2002) 46(8):2636-9. doi:10.1128/AAC.46.8.2636-2639.2002
34. Elvers KT, Wright SJ. Antibacterial activity of the anti-inflammatory compound ibuprofen. Lett Appl Microbiol (1995) 20(2):82-4. doi:10.1111/j.1472-765X.1995.tb01291.x
35. Simonetti A, Marzi S, Billas IM, Tsai A, Fabbretti A, Myasnikov AG, et al. Involvement of protein IF2 N domain in ribosomal subunit joining revealed from architecture and function of the full-length initiation factor. Proc Natl Acad Sci U S A (2013) 110(39):15656-61. doi:10.1073/pnas.1309578110
36. Guzman JD, Evangelopoulos D, Gupta A, Birchall K, Mwaigwisya S, Saxty B, et al. Antitubercular specific activity of ibuprofen and the other 2-arylpropanoic acids using the HT-SPOTi whole-cell phenotypic assay. BMJ Open (2013) 3(6):e002672. doi:10.1136/bmjopen-2013-002672
37. Yin Z, Wang Y, Whittell LR, Jergic S, Liu M, Harry E, et al. DNA replication is the target for the antibacterial effects of nonsteroidal anti-inflammatory drugs. Chem Biol (2014) 21(4):481-7. doi:10.1016/j.chembiol.2014.02.009
38. Denkin S, Byrne S, Jie C, Zhang Y. Gene expression profiling analysis of Mycobacterium tuberculosis genes in response to salicylate. Arch Microbiol (2005) 184(3):152-7. doi:10.1007/s00203-005-0037-9
39. Dastidar SG, Ganguly K, Chaudhuri K, Chakrabarty AN. The anti-bacterial action of diclofenac shown by inhibition of DNA synthesis. Int J Antimicrob Agents (2000) 14(3):249-51. doi:10.1016/S0924-8579(99)00159-4
40. Annadurai S, Basu S, Ray S, Dastidar SG, Chakrabarty AN. Antibacterial activity of the antiinflammatory agent diclofenac sodium. Indian J Exp Biol (1998) 36(1):86-90.
41. Sriram D, Yogeeswari P, Devakaram RV. Synthesis, in vitro and in vivo antimycobacterial activities of diclofenac acid hydrazones and amides. Bioorg Med Chem (2006) 14(9):3113-8. doi:10.1016/j.bmc.2005.12.042
42. Kalle AM, Rizvi A. Inhibition of bacterial multidrug resistance by celecoxib, a cyclooxygenase-2 inhibitor. Antimicrob Agents Chemother (2011) 55(1):439-42. doi:10.1128/AAC.00735-10
43. Patel VA, Dunn MJ, Sorokin A. Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2. J Biol Chem (2002) 277(41):38915-20. doi:10.1074/jbc.M206855200
44. Salunke SB, Azad AK, Kapuriya NP, Balada-Llasat JM, Pancholi P, Schlesinger LS, et al. Design and synthesis of novel anti-tuberculosis agents from the celecoxib pharmacophore. Bioorg Med Chem (2015) 23(9):1935-43. doi:10.1016/j.bmc.2015.03.041
45. Gold B, Pingle M, Brickner SJ, Shah N, Roberts J, Rundell M, et al. Nonsteroidal anti-inflammatory drug sensitizes Mycobacterium tuberculosis to endogenous and exogenous antimicrobials. Proc Natl Acad Sci U S A (2012) 109(40):16004-11. doi:10.1073/pnas.1214188109
46. Chiniforoshan H, Tabrizi L, Hadizade M, Sabzalian MR, Chermahini AN, Rezapour M. Anti-inflammatory drugs interacting with Zn (II) metal ion based on thiocyanate and azide ligands: synthesis, spectroscopic studies, DFT calculations and antibacterial assays. Spectrochim Acta A Mol Biomol Spectrosc (2014) 128:183-90. doi:10.1016/j.saa.2014.02.135
47. Kovala-Demertzi D, Dokorou V, Primikiri A, Vargas R, Silvestru C, Russo U, et al. Organotin meclofenamic complexes: synthesis, crystal structures and antiproliferative activity of the first complexes of meclofenamic acid-novel anti-tuberculosis agents. J Inorg Biochem (2009) 103(5):738-44. doi:10.1016/j.jinorgbio.2009.01.014
48. Dutta NK, Annadurai S, Mazumdar K, Dastidar SG, Kristiansen JE, Molnar J, et al. Potential management of resistant microbial infections with a novel non-antibiotic: the anti-inflammatory drug diclofenac sodium. Int J Antimicrob Agents (2007) 30(3):242-9. doi:10.1016/j.ijantimicag.2007.04.018
49. Mitchison DA, Davies GR. Assessment of the efficacy of new anti-tuberculosis drugs. Open Infect Dis J (2008) 2:59-76. doi:10.2174/1874279300802010059